Munoz V Terrones, Triffet A, Cauchie P, Brohée D
Service d'Oncologie, C.H.U. de Charleroi, Site André Vésale, Montigny-le-Tilleul.
Rev Med Brux. 2008 Nov-Dec;29(6):535-9.
L-asparaginase is commonly used in the chemotherapy regimens for acute lymphoblastic leukaemia. Its use is associated with thrombotic complications in 1 to 14 % of the cases. The pathogenesis of this complication is still unclear. However, the decrease of antithrombin seems to play an important role. We report a case of a 17-year old man with a acute lymphoblastic leukaemia, who developed a cerebral sinovenous thrombosis due to an acquired deficiency of antithrombin and protein C and S following L-asparaginase chemotherapy. We discuss the use of prophylactic supplements of antithrombin and the value of screening of thrombophilia based on the recent medical literature.
L-天冬酰胺酶常用于急性淋巴细胞白血病的化疗方案。在1%至14%的病例中，其使用与血栓形成并发症有关。这种并发症的发病机制仍不清楚。然而，抗凝血酶的减少似乎起着重要作用。我们报告一例17岁男性急性淋巴细胞白血病患者，在接受L-天冬酰胺酶化疗后，因获得性抗凝血酶及蛋白C和S缺乏而发生脑静脉窦血栓形成。我们根据最近的医学文献讨论抗凝血酶预防性补充剂的使用以及血栓形成倾向筛查的价值。
